Thursday, Nov. 7, 2019
8 a.m. – 5 p.m.
Program Purpose
Immunotherapy treatments inherently rely on the presence of immune cells, both systemic and localized to the tumor microenvironment. Immunologically “hot” tumors, such as melanoma, have demonstrated enhanced responses to immunotherapy treatments; however, many tumors are “cold”, lacking the necessary immune components for a successful treatment. Many techniques, including radiotherapy, synthetic immunomodulators, oncolytic viruses, and certain systemic treatments, have been shown to manipulate the immune status of the treated tumor microenvironment, and even those tumor sites elsewhere in the body (abscopal effects). Such manipulations can increase the presence of desirable immune infiltrates and potentially lead to favorable treatment outcomes. In this workshop, the current status of intratumoral immunomodulation will be presented and future directions for the field will be discussed, along with their implications for current and forthcoming immunotherapy treatments.
Intended Audience
The intended audience for this program includes: basic scientists and clinical investigators from academic institutions, venture capital, industry, and regulatory agencies. Additional audiences benefiting from this program include clinicians, graduate students, and postdoctoral fellows involved in cancer research and its translation into clinical practice.
Workshop Organizers
- Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute at The Icahn School of Medicine at Mount Sinai
- Adi Diab, MD – The University of Texas MD Anderson Cancer Center
Educational Objectives
Upon Completion of this meeting, participants will be able to:
- Describe the importance of the intratumoral immune environment and its implications for cancer treatment outcomes
- Discuss the role and mechanisms of radiation treatments in intratumoral immunomodulation
- Understand the effects of intratumoral synthetic immunomodulators and oncolytic viral therapies on the tumor microenvironment
- Explain the impact that systemic combination treatments may have on local intratumoral immunomodulation as well as the impact localized treatment can have on the immune status of the rest of the body
SITC's Workshop on Intratumoral Immunomodulation is supported in part by grants from Amgen, Celgene Corporation, Idera Pharmaceuticals and Pfizer, Inc. (as of November 6, 2019)
Program Schedule
| Thursday, Nov. 7, 2019 |
|
| 8 a.m. |
Introduction
Adi Diab, MD – University of Texas MD Anderson Cancer Center
|
| Session 1: Introduction to Intratumoral Immunomodulation |
Time:
|
8:05 – 9:15 a.m.
|
| 8:05 a.m. |
Introduction to Intratumoral Therapy
Aurélien Marabelle, MD, PhD – Gustave Roussy
|
| 8:35 a.m. |
Cold vs. Hot Tumors
Razvan Cristescu, PhD - Merck
|
| 8:55 a.m. |
Clinical Assessment of Intratumoral Immunomodulation
Jianda Yuan, MD, PhD – Merck Research Laboratories
|
| Session 2: Modes of Delivery |
| Time: |
9:15 – 10:15 a.m.
|
| 9:15 a.m. |
Intratumoral Immunotherapies from an Interventional Radiology Perspective
Rahul Sheth, MD – The University of Texas MD Anderson Cancer Center
|
| 9:35 a.m. |
Attracting Dendritic Cells to the Tumor with Focal Radiotherapy
Sandra Demaria, MD – Weill Cornell Medicine
|
| 9:55 a.m. |
SBRT and Immune Activation
Silvia Formenti, MD – New York-Presbyterian/Weill Cornell Medical Center
|
| 10:15 a.m. |
Break
|
| Session 3: Intratumoral Synthetic Modulators |
| Time |
10:40 a.m. – 12 p.m.
|
| 10:40 a.m. |
Hot is Not Enough: In Situ Vaccination to Turn Cold Tumors Hot, and Cross-Priming
Joshua Brody, MD – Icahn School of Medicine at Mount Sinai
|
| 11 a.m. |
TLR9
Adi Diab, MD – University of Texas MD Anderson Cancer Center
|
| 11:20 a.m |
TLR7/8 Agonists in Immuno-Oncology
Willem W. Overwijk, PhD – Nektar Therapeutics
|
| 11:40 a.m. |
STING at a Crossroads: Untapped Potential for Innate Immunity
Thomas W. Dubensky, PhD – Tempest Therapeutics
|
| 12 p.m. |
Lunch
|
| Session 4: Intratumoral Oncolytic Modulators |
| Time: |
1 – 2 p.m.
|
| 1 p.m. |
The Role of T-VEC and Other Oncolytic Viruses in Priming the Tumor Microenvironment for Immunotherapy
Howard L. Kaufman, MD, FACS – Replimune Group Inc.
|
| 1:20 p.m. |
Intratumoral Oncolytic Immunotherapy: Is Lysis Really Necessary?
Dmitry Zamarin, MD, PhD – Memorial Sloan Kettering Cancer Center
|
| 1:40 p.m. |
Development of Multiplex Oncolytic Viruses
John Bell, PhD – University of Ottawa
|
|
Session 5: Systemic Combinations
|
Time:
|
2 – 4:55 p.m.
|
| 2 p.m. |
Intratumoral Checkpoint Blockade Inhibition
Craig L. Slingluff, MD – University of Virginia
|
| 2:20 p.m. |
Anti-Tumor Vaccines Platforms
Esteban Celis, MD, PhD – Augusta University
|
| 2:40 p.m. |
Break
|
| 3 p.m. |
CD40: A Target for Systemic Immune Modulation
Michael Yellin, MD – Celldex Therapeutics, Inc.
|
| 3:20 p.m. |
Modulating the Tumor Microenvironment
Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai |
| 3:40 p.m. |
Regulatory Implications for Drug Development
Maitreyee Hazarika, MD – U.S Food and Drug Administration
|
| 4 p.m. |
Systemic Combinations Panel Discussion
Moderators: Adi Diab, MD – University of Texas MD Anderson Cancer Center
Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai
Panelists:
Esteban Celis, MD, PhD – Augusta University
Maitreyee Hazarika, MD – U.S Food and Drug Administration
Jason Luke, MD, FACP – UPMC
Craig L. Slingluff, MD – University of Virginia
Michael Yellin, MD – Celldex Therapeutics, Inc.
Jianda Yuan, MD, PhD – Merck Research Laboratories
|
| 4:55 p.m. |
Closing
Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai
|
| 5 p.m. |
Adjourn
|